Author Affiliations: Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago.
We read with interest the article by Lowder et al1 on the outcomes of the dexamethasone intravitreal implant for treatment of noninfectious intermediate or posterior uveitis. Lowder et al1 found that the implant was able to significantly reduce intraocular inflammation and improve visual acuity for 6 months in patients with uveitis. Also, fewer than 5% of eyes developed an intraocular pressure (IOP) of 35 mm Hg or greater, and fewer than 10% of eyes developed an IOP of 25 mm Hg or greater. Approximately one-quarter of patients required topical antihypertensive therapy for IOP control, with few requiring more than 1 medication over the 26-week study. No eyes required surgical intervention for management of elevated IOP.1
Saraiya NV, Patel SS, Goldstein DA. A Report of High Intraocular Pressure With the Dexamethasone Intravitreal Implant. Arch Ophthalmol. 2011;129(12):1638–1640. doi:10.1001/archophthalmol.2011.355
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: